Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
More Reading from MarketBeat.com Why Boston Scientific's Big Dip Could Be a Bigger OpportunityReported by Nathan Reiff. Originally Published: 3/24/2026. 
Key Points - Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) has gotten off to a rough start this year: shares are down about 26% year-to-date (YTD) and nearly a third over the past year. Yet a closer look at the healthcare company's fundamentals shows some solid results recently, including adjusted earnings per share (EPS) of $0.80 in the most recent quarter, two cents above consensus. Indeed, a detailed review of Boston Scientific's earnings indicates the company is performing well—its electrophysiology (EP) segment, and Watchman products in particular, have grown rapidly and appear poised to continue doing so. The company is also expected to release results from its Champion-AF trial by the end of March; positive data could substantially expand Watchman's addressable patient base. Investors may be tempted to buy the dip in BSX, but it's important to remember why shares have fallen and what risks remain. Is the Boston Scientific Dip Justified? Shares of BSX dropped after the company's February earnings release, despite revenue rising roughly 16% year over year (YOY) and adjusted EPS topping expectations. Free cash flow also improved significantly, increasing about 38% YOY to roughly $3.7 billion. The selloff appears to be driven largely by the company's 2026 organic revenue guidance, which forecasts YOY growth of 10% to 11%—well below 2025's roughly 20% full-year growth. Part of the slowdown is attributed to the near-term impact of discontinuing certain Axios catheter products and other lines earlier in the year; management estimates this will shave about 150 basis points off early-2026 growth. That said, much of Boston Scientific's business remains intact, growing and efficient. The company is guiding for another year of rising free cash flow—about $4.2 billion anticipated in 2026—along with continued operating-margin expansion and other improvements. The Champion Trial Could Be a Catalyst for Reversal A key potential catalyst is the Champion trial, which compares the Watchman stroke-reduction implant to oral anticoagulation. If the trial is positive, the addressable patient pool for Watchman could roughly quadruple to about 20 million, a meaningful expansion. Positive Champion results could therefore drive sustained sales growth globally by identifying millions of additional potential patients. Another growth driver could be the planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). Penumbra's products would give Boston Scientific an entry into the mechanical thrombectomy market, where it currently has no presence. The $14.5 billion deal is financed in part by a $6 billion term loan secured in late February. While that adds near-term financial pressure, the company's improving free cash flow and solid fundamentals may help mitigate investor concerns. Risks and Analyst Perspectives Are Worth Keeping in Mind A negative Champion result would be the biggest risk to Boston Scientific's growth thesis. It would undercut expectations for accelerating Watchman sales and could make the company's 10%–11% organic revenue guidance for 2026 harder to achieve. Meanwhile, Wall Street remains largely optimistic. Of 25 analyst ratings, 23 are Buys and two are Holds. Several firms—including Stifel Nicolaus, Jefferies and Truist Financial—reissued Buy ratings in March, though some have tempered their price targets while keeping Buy recommendations. Still, analysts see significant upside: the consensus price target of $106.27 is more than 50% above the current trading price of BSX. | 
Post a Comment
Post a Comment